Harrow Health Inc (HROW) shares surged 5.13% in pre-market trading on Friday, following the company's impressive fourth-quarter and year-end 2024 financial results released after the bell on Thursday. The pharmaceutical and drug compounding company significantly outperformed market expectations, driving investor enthusiasm.

Harrow reported adjusted earnings of $0.24 per share for the quarter ended December 31, substantially beating the Zacks Consensus Estimate of $0.11 per share. This represents a remarkable turnaround from the loss of $0.27 per share in the same quarter last year. The company's revenue soared to $66.83 million, an 83.8% increase year-over-year, surpassing analyst expectations of $61.79 million. Notably, Harrow achieved a core gross margin of 84% and an overall gross margin of 79% for the quarter.

The strong financial performance has reinforced positive sentiment among analysts. The current average analyst rating on Harrow shares is "buy," with five "strong buy" or "buy" recommendations. Wall Street's median 12-month price target for Harrow Inc stands at $57.00, suggesting significant upside potential. As the company continues to demonstrate growth in its pharmaceuticals business, investors appear optimistic about its future prospects, despite the stock's 17.6% decline since the beginning of the year.